Product image of Nimbex (Cisatracurium Besilate) supplied by GNH India

Nimbex

Active Ingredient:
Cisatracurium Besilate
Origin:
EU

Nimbex (Cisatracurium Besilate)

Cisatracurium Besilate, the active ingredient in Nimbex, is a non‑depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation, provides skeletal muscle relaxation during surgery, and serves as an adjunct to mechanical ventilation.

GNH India supplies Nimbex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict GMP conditions, ensuring consistent potency and safety for clinical use.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nimbex, a non‑depolarizing neuromuscular blocker, is employed in clinical situations that require rapid and controlled skeletal muscle relaxation.

  • Facilitation of endotracheal intubation: provides rapid muscle relaxation to enable safe airway placement.
  • Muscle relaxation during surgery: maintains profound paralysis throughout operative procedures.
  • Adjunct to mechanical ventilation: prevents spontaneous breathing efforts, allowing controlled ventilation in intensive care.
  • Diagnostic procedures requiring muscle relaxation: assists in procedures such as bronchoscopy where patient movement must be minimized.

How It Works

  • Cisatracurium besilate competitively binds to nicotinic acetylcholine receptors at the motor end‑plate of the neuromuscular junction, preventing acetylcholine from opening the ion channel. This blockade inhibits depolarization of the muscle membrane, resulting in a dose‑dependent paralysis of skeletal muscles. The drug is eliminated primarily by Hofmann degradation, a temperature‑ and pH‑dependent chemical process, making its clearance independent of renal or hepatic function.

Side Effects

Cisatracurium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Flushing or erythema
  • Transient hypotension
  • Tachycardia

Serious or Rare Side Effects

  • Anaphylactic reaction
  • Prolonged neuromuscular paralysis
  • Severe hypotension or cardiovascular collapse

Precautions & Warnings

Cisatracurium requires careful patient assessment and monitoring to minimize risks.

  • Renal or hepatic impairment: dosing generally does not require adjustment but monitor for unexpected prolonged effects.
  • Known hypersensitivity to cisatracurium or related compounds: avoid use.
  • Concurrent use of other neuromuscular blocking agents: assess additive paralysis.
  • Patients with neuromuscular diseases (e.g., myasthenia gravis): may experience exaggerated block.
  • Electrolyte abnormalities such as hypermagnesemia: can intensify blockade.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cisatracurium can interact with several drugs, influencing the depth and duration of muscle relaxation.

Major Interactions (Avoid)

  • Potassium channel blockers (e.g., aminoglycoside antibiotics): may cause profound paralysis.
  • Magnesium sulfate: can markedly enhance neuromuscular block.
  • Concurrent non‑depolarizing neuromuscular blockers: additive effect leading to excessive paralysis.

Moderate Interactions (Monitor Closely)

  • Inhalational anesthetics (e.g., sevoflurane): may increase block duration.
  • Certain antibiotics such as clindamycin or tetracyclines: can potentiate effect.
  • Lithium therapy: may prolong neuromuscular blockade.

Frequently Asked Questions

Nimbex (cisatracurium besilate) is used to produce skeletal muscle relaxation in a controlled manner. It is indicated for facilitating endotracheal intubation, providing muscle paralysis during surgical procedures, and serving as an adjunct to mechanical ventilation in intensive‑care settings.

Cisatracurium besilate acts by competitively blocking nicotinic acetylcholine receptors at the neuromuscular junction. By preventing acetylcholine‑induced depolarization, it stops the transmission of nerve impulses to the muscle, resulting in dose‑dependent skeletal muscle paralysis.

The dose of Nimbex is individualized by the prescribing clinician based on factors such as the patient’s weight, the required depth of muscle relaxation, the type of procedure, and real‑time neuromuscular monitoring. No fixed regimen is provided here.

Safety data for cisatracurium besilate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nimbex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with agents such as rocuronium, cisatracurium (Nimbex) is eliminated largely by Hofmann degradation, making its clearance independent of renal or hepatic function. This can be advantageous in patients with organ impairment, while onset may be slightly slower than some aminosteroid blockers.

Nimbex should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Nimbex is supplied as an injectable solution for intravenous use. It can be given as a bolus dose to achieve rapid onset, followed by a continuous infusion or intermittent dosing to maintain the desired level of muscle relaxation, as directed by the clinician.

The most serious risks include anaphylactic reactions, prolonged or unexpected neuromuscular paralysis, severe hypotension or cardiovascular collapse, and rare malignant‑hyperthermia‑like events. Prompt recognition and appropriate supportive measures are essential.

Nimbex should be avoided in patients with a known hypersensitivity to cisatracurium or any component of the formulation. Caution is also advised for individuals with severe electrolyte disturbances, especially hypermagnesemia, and those with certain neuromuscular disorders where exaggerated blockade may occur.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.